LONDON – Astellas Pharma Ltd.'s one-year suspension from the Association of the British Pharmaceutical Association (ABPI) has been extended for a further 12 months, with a warning that the Tokyo-based company faces expulsion if further checks, due in October 2017, do not show compliance.